Literature DB >> 23319845

Vismodegib (erivedge) for advanced Basal cell carcinoma.

Chris Fellner.   

Abstract

Vismodegib (Erivedge) for advanced basal cell carcinoma.

Entities:  

Year:  2012        PMID： 23319845      PMCID： PMC3541861     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  36 in total

Review 1.  Basal cell carcinoma.

Authors:  C S M Wong; R C Strange; J T Lear
Journal:  BMJ       Date:  2003-10-04

Review 2.  Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Authors:  Robert W Carlson; Clifford A Hudis; Kathy I Pritchard
Journal:  J Natl Compr Canc Netw       Date:  2006-11       Impact factor: 11.908

Review 3.  Basal-cell carcinoma.

Authors:  Adam I Rubin; Elbert H Chen; Désirée Ratner
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 4.  Long-term survival following nodal metastases from basal cell carcinoma.

Authors:  R L Raszewski; B Guyuron
Journal:  Ann Plast Surg       Date:  1990-02       Impact factor: 1.539

Review 5.  Etiology and pathogenesis of basal cell carcinoma.

Authors:  S J Miller
Journal:  Clin Dermatol       Date:  1995 Nov-Dec       Impact factor: 3.541

Review 6.  Biology of basal cell carcinoma (Part II).

Authors:  S J Miller
Journal:  J Am Acad Dermatol       Date:  1991-02       Impact factor: 11.527

7.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.

Authors:  G Bhardwaj; B Murdoch; D Wu; D P Baker; K P Williams; K Chadwick; L E Ling; F N Karanu; M Bhatia
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

Review 8.  Basal cell carcinomas: attack of the hedgehog.

Authors:  Ervin H Epstein
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

Review 9.  Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.

Authors:  Suzie J Scales; Frederic J de Sauvage
Journal:  Trends Pharmacol Sci       Date:  2009-05-13       Impact factor: 14.819

Review 10.  Biology of basal cell carcinoma (Part I).

Authors:  S J Miller
Journal:  J Am Acad Dermatol       Date:  1991-01       Impact factor: 11.527
View more
  18 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Enhanced skin delivery of vismodegib by microneedle treatment.

Authors:  Hiep X Nguyen; Ajay K Banga
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

3.  Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.

Authors:  Waleed Kian; Laila C Roisman; Iris M Goldstein; Abed Abo-Quider; Benzion Samueli; Nadav Wallach; Farouq Alguayn; Walid Shalata; Dina Levitas; Olga Belochitski; Daniel Levin; Eyal Fenig; Konstantin Lavrenkov; Margarita Tokar; Nir Peled; Alexander Yakobson
Journal:  JCO Precis Oncol       Date:  2020-04-30

Review 4.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.

Authors:  Vivian T Yin; Helen Merritt; Bita Esmaeli
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

Review 5.  Advanced basal cell carcinoma.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2013-04-16

6.  The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose.

Authors:  Orit Markowitz; Michelle Schwartz
Journal:  J Clin Aesthet Dermatol       Date:  2016-08-01

Review 7.  Targeting the Hedgehog Pathway in Pediatric Medulloblastoma.

Authors:  Sherri Y Huang; Jer-Yen Yang
Journal:  Cancers (Basel)       Date:  2015-10-23       Impact factor: 6.639

Review 8.  Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma.

Authors:  Nancy M Nix; Olivia Burdine; Makeda Walker
Journal:  J Adv Pract Oncol       Date:  2014 Jul-Aug

9.  Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

Authors:  C D'Amato; R Rosa; R Marciano; V D'Amato; L Formisano; L Nappi; L Raimondo; C Di Mauro; A Servetto; F Fulciniti; A Cipolletta; C Bianco; F Ciardiello; B M Veneziani; S De Placido; R Bianco
Journal:  Br J Cancer       Date:  2014-08-05       Impact factor: 7.640

10.  Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma".

Authors:  Fergal C Kelleher; Antonella Viterbo
Journal:  Cancers (Basel)       Date:  2013-02-22       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.